ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2570

Urinary Cellular Profile as a Biomarker for Proliferative Lupus Nephritis

Amira El Gerby 1, Abeer Abdelati 2, Hanaa Donia 3 and Nouran Eshak4, 1Rheumatology Department, Faculty of Medicine, Alexandria University, Egypt, Alexandria, Egypt, 2alexandria university, alexandria, Egypt, 3Clnical and Chemical Pathology Department, Faculty of Medicine, ALexandria University, Alexandria, Egypt, 4Rheumatology Unit, Internal Medicine Department, Faculty of Medicine, Alexandria University, Lubbock, TX

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Lupus nephritis, lymphocytes, Urinary Biomarkers and macrophages

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 12, 2019

Title: SLE – Clinical Poster III: Treatment

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Proliferative lupus nephritis (LN) is one of the most common and serious manifestations of SLE and is a major cause of morbidity. A search for the ideal biomarker for LN is still underway, one that can be used for early detection, and correlate with the class & activity of LN. Urine is normally devoid of leucocytes, however, it has been observed that macrophages and T-lymphocytes are routinely present in the urine of LN patients and those with other proliferative renal diseases. This provided the idea for their potential use as biomarkers for proliferative LN. The objective is to study the urinary CD4+, CD8+ T Lymphocytes, and CD14+ monocytes in patients with proliferative lupus nephritis, and explore their use as a biomarker for LN. 

Methods: Our subjects included 30 patients with biopsy-proven proliferative LN (Group A) and 30 SLE patients without clinical or lab evidence of LN as controls (Group B). Laboratory investigations included serum creatinine, urine analysis, protein: creatinine ratio, anti-ds DNA Ab, C3 and C4. For the flow cytometric analysis, 100 ml of freshly voided urine in a sterile container were obtained from patients and controls. All samples were processed within 2-4 hours of collection to ensure viability of the cells. Urine mononuclear cell count was done using a hemocytometer. The urine samples were centrifuged then washed twice by phosphate-buffered saline/bovine serum albumin (PBS/BSA) & re-suspended in about 300 μls PBS. The cells were stained with anti CD8- FITC, anti CD4- PE, anti CD14-PERCP and anti- CD3-APC monoclonal antibodies. The flow cytometric analysis was done using Becton Dickinson, FACS Calibur multi-parameter flow cytometer equipped with BD CellQuest Pro software for data analysis. 

Results:  CD14 + cells were the most abundant cells in the urine of LN patients. The mean numbers of urinary CD8+, CD4+ and CD14+ cells/ml were significantly higher in patients with LN (405.6 ± 200.0, 281.1 ± 195.3, and 1554.7 ± 606.8 respectively) than in those without (39.30 ± 17.56, 34.33 ± 16.41, and 161.17 ± 90.91 respectively). AUC for ROC = 1.0 for all 3 markers with CD8+ >85 cells/ml, CD4+ >80 cells/ml, and CD14+ >400cells/ml being observed exclusively in LN. 
The cell counts correlated significantly with the protein: creatinine ratio, but not with other markers of disease activity.  
The CD4: CD8 ratio was significantly lower in LN patients (0.69 ± 0.21) than in those without (0.91 ± 0.31).
Urinary CD14+ cells seem to occur in much higher counts in Class IV (1736.7
± 522.0) than Class III LN (898.5 ± 17.68) p=0.084. 

Conclusion: Urinary CD8+, CD4+, and CD14+ cells are highly sensitive and specific markers for detecting proliferative LN. A low CD4: CD8 ratio provides a further clue. The cell counts correlate with proteinuria. CD14 cell counts may be a potential biomarker to differentiate between the different classes of proliferative LN. 

Comparison between the two groups according to CD3+ CD8+/ml, CD3+ CD4+/ml and CD14+/ml

Comparison between the different classes of LN according to CD3+ CD8+/ml, CD3+ CD4+/ml and CD14+/ml.

A dot plot of flow cytometric analysis of urinary T cells and monocytes in a patient with lupus nephritis showing increased both CD4+ and CD8+ T cells and macrophages -dim CD4 expression and CD14 positive -not shown–


Disclosure: A. El Gerby, None; A. Abdelati, None; H. Donia, None; N. Eshak, None.

To cite this abstract in AMA style:

El Gerby A, Abdelati A, Donia H, Eshak N. Urinary Cellular Profile as a Biomarker for Proliferative Lupus Nephritis [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/urinary-cellular-profile-as-a-biomarker-for-proliferative-lupus-nephritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/urinary-cellular-profile-as-a-biomarker-for-proliferative-lupus-nephritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology